16 • Probe •Vol LXII • No. 3 • May–Aug 2023 Clinical Evidence 1 Efficacy of Liv.52® in the Management of Infective Hepatitis, Chronic Active Hepatitis, and Cirrhosis Aim To assess the efficacy of Liv.52 in the management of various liver diseases such as acute infective (viral) hepatitis, chronic active hepatitis, and cirrhosis Materials and Methods This controlled study included 104 patients, of whom 73 patients were treated with Liv.52 (at a dosage of 4 tablets, TID) and 31 patients served as controls. The number of patients in each category is presented in the Table. Table. Categories of Liver Diseases Type of Liver Disease Liv.52 Group, n Control Group, n Infective Hepatitis (Group A) 30 15 Chronic Active Hepatitis (Group B) 24 8 Cirrhosis (Group C) 19 8 The patients were analyzed for clinical parameters and improvements in the biochemical profile, liver function parameters, and histopathologic findings after a follow-up of 3 years. The results were graded as “good”, “fair”, and “poor” upon analysis of the data after the full study. Results Group A: infective hepatitis Clinical improvement Symptoms such as fever, anorexia, nausea, weakness, bone ache, headache, sleeplessness, flatulence, and epigastric discomfort were alleviated sooner in the Liv.52 group than in the control group. Biochemical profile (liver function tests) • Serum bilirubin: In the Liv.52 group, the serum bilirubin level reduced in most patients, within 7 days of treatment. Moreover, the level became normal or near normal in 73.33% of the patients within 2 to 3 weeks of the treatment. The trend of the changes in the serum bilirubin level is shown in the Figure. • Alkaline phosphatase (ALP): The level of ALP decreased faster in most patients (73.33%) in the Liv.52 group than in the control group (26.66%). • Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT): In the Liv.52 group, 22 patients (73.33%) showed early improvement (within 2–3 wk), whereas 26.66% of the patients in the control group showed the same response within the same time frame. • Serum albumin: The serum albumin level significantly increased earlier in most patients in the Liv.52 group compared with that in the control group. Group B: chronic active hepatitis Clinical improvement Most patients in the Liv.52 group experienced alleviation in symptoms such as fever, anorexia, yellow Figure. Effect of Liv.52 on Serum Bilirubin Level in Infective Hepatitis 7 5 2 1 3 4 6 8 0 0 1 2 3 4 5 6 Week mg/100 mL Liv.52 Group Control Group
RkJQdWJsaXNoZXIy MjAwNDg=